Literature DB >> 30622219

Poldip2 deficiency protects against lung edema and vascular inflammation in a model of acute respiratory distress syndrome.

Steven J Forrester1, Qian Xu1,2, Daniel S Kikuchi1, Derick Okwan-Duodu1, Ana Carolina Campos1, Elizabeth A Faidley1, Guogang Zhang2, Bernard Lassègue1, Ruxana T Sadikot3,4, Kathy K Griendling1, Marina S Hernandes5.   

Abstract

Acute respiratory distress syndrome (ARDS) in a deadly disease that can be brought on by endotoxins such as lipopolysaccharide (LPS). ARDS is characterized by vascular permeability, a severe inflammatory response, lung leukocyte infiltration, and resultant lung edema. Polymerase δ-interacting protein 2 (Poldip2) is a novel regulator of blood-brain barrier permeability; however, its role in regulating lung permeability and vascular inflammation is unknown. Here, the role of Poldip2 in regulating vascular permeability and inflammation in a mouse model of ARDS was assessed. Heterozygous deletion of Poldip2 was found to reduce LPS-induced mortality within 20 h, lung inflammatory signaling, and leukocyte infiltration. Moreover, reduced Poldip2-suppressed LP-induced vascular cell adhesion molecule (VCAM)-1 induction, leukocyte recruitment, and mitochondrial reactive oxygen species (ROS) production in vitro These data indicate that Poldip2 is an important regulator of the debilitating consequences of ARDS, potentially through the regulation of mitochondrial ROS-induced inflammatory signaling. Consequently, inhibition of Poldip2 may be a viable option for therapeutic discovery moving forward.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Poldip2; acute respiratory distress syndrome; inflammation; leukocyte

Mesh:

Substances:

Year:  2019        PMID: 30622219      PMCID: PMC7954131          DOI: 10.1042/CS20180944

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  42 in total

1.  Comparative methods for multiplex analysis of cytokine protein expression in plasma of lipopolysaccharide-treated mice.

Authors:  Walter F Bobrowski; J Eric McDuffie; Gregg Sobocinski; Jonathan Chupka; Eric Olle; Amy Bowman; Mudher Albassam
Journal:  Cytokine       Date:  2005-10-28       Impact factor: 3.861

Review 2.  New insights into the mechanisms of pulmonary edema in acute lung injury.

Authors:  Raquel Herrero; Gema Sanchez; Jose Angel Lorente
Journal:  Ann Transl Med       Date:  2018-01

3.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

Authors:  M J Elices; L Osborn; Y Takada; C Crouse; S Luhowskyj; M E Hemler; R R Lobb
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

Review 4.  The acute respiratory distress syndrome: pathogenesis and treatment.

Authors:  Michael A Matthay; Rachel L Zemans
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

5.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells.

Authors:  Alicia N Lyle; Nita N Deshpande; Yoshihiro Taniyama; Bonnie Seidel-Rogol; Lily Pounkova; Pingfeng Du; Christopher Papaharalambus; Bernard Lassègue; Kathy K Griendling
Journal:  Circ Res       Date:  2009-07-02       Impact factor: 17.367

7.  Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation.

Authors:  Rajesh Kumar Gandhirajan; Shu Meng; Harish C Chandramoorthy; Karthik Mallilankaraman; Salvatore Mancarella; Hui Gao; Roshanak Razmpour; Xiao-Feng Yang; Steven R Houser; Ju Chen; Walter J Koch; Hong Wang; Jonathan Soboloff; Donald L Gill; Muniswamy Madesh
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

Review 8.  Polymerase δ-interacting Protein 2: A Multifunctional Protein.

Authors:  Marina S Hernandes; Bernard Lassègue; Kathy K Griendling
Journal:  J Cardiovasc Pharmacol       Date:  2017-06       Impact factor: 3.105

9.  Acute Respiratory Distress Syndrome.

Authors:  B Taylor Thompson; Rachel C Chambers; Kathleen D Liu
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

Review 10.  Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms.

Authors:  Simona-Adriana Manea; Alina Constantin; Gina Manda; Shlomo Sasson; Adrian Manea
Journal:  Redox Biol       Date:  2015-06-25       Impact factor: 11.799

View more
  10 in total

1.  Knockdown of lncRNA MALAT1 Alleviates LPS-Induced Acute Lung Injury via Inhibiting Apoptosis Through the miR-194-5p/FOXP2 Axis.

Authors:  Chuan-Chuan Nan; Ning Zhang; Kenneth C P Cheung; Hua-Dong Zhang; Wei Li; Cheng-Ying Hong; Huai-Sheng Chen; Xue-Yan Liu; Nan Li; Lixin Cheng
Journal:  Front Cell Dev Biol       Date:  2020-10-07

2.  The effects of sepsis on endothelium and clinical implications.

Authors:  Elena V Dolmatova; Keke Wang; Rohan Mandavilli; Kathy K Griendling
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

3.  Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome.

Authors:  Ziwei Ou; Elena Dolmatova; Rohan Mandavilli; Hongyan Qu; Georgette Gafford; Taylor White; Alejandra Valdivia; Bernard Lassègue; Marina S Hernandes; Kathy K Griendling
Journal:  J Am Heart Assoc       Date:  2022-05-10       Impact factor: 6.106

4.  Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy.

Authors:  Daniel S Kikuchi; Ana Carolina P Campos; Hongyan Qu; Steven J Forrester; Rosana L Pagano; Bernard Lassègue; Ruxana T Sadikot; Kathy K Griendling; Marina S Hernandes
Journal:  J Neuroinflammation       Date:  2019-11-28       Impact factor: 8.322

5.  Characterization of Poldip2 knockout mice: Avoiding incorrect gene targeting.

Authors:  Bernard Lassègue; Sandeep Kumar; Rohan Mandavilli; Keke Wang; Michelle Tsai; Dong-Won Kang; Catherine Demos; Marina S Hernandes; Alejandra San Martín; W Robert Taylor; Hanjoong Jo; Kathy K Griendling
Journal:  PLoS One       Date:  2021-12-20       Impact factor: 3.240

6.  NR4A1 Promotes LPS-Induced Acute Lung Injury through Inhibition of Opa1-Mediated Mitochondrial Fusion and Activation of PGAM5-Related Necroptosis.

Authors:  Pingjun Zhu; Junyan Wang; Wenjuan Du; Jun Ren; Ying Zhang; Fei Xie; Guogang Xu
Journal:  Oxid Med Cell Longev       Date:  2022-02-18       Impact factor: 6.543

7.  Poldip2/Nox4 Mediates Lipopolysaccharide-Induced Oxidative Stress and Inflammation in Human Lung Epithelial Cells.

Authors:  Yueguo Wang; Zhenxing Ding; Youhui Tu; Xu Wu; Wenying Zhang; Shuang Ji; Jilong Shen; Li Zhang; Huimei Wu; Guanghe Fei
Journal:  Mediators Inflamm       Date:  2022-01-30       Impact factor: 4.711

8.  Secondary Dysfunction of the Intestinal Barrier in the Pathogenesis of Complications of Acute Poisoning.

Authors:  Ju Ju Ivnitsky; T V Schäfer; V L Rejniuk; O A Vakunenkova
Journal:  J Evol Biochem Physiol       Date:  2022-08-28       Impact factor: 1.621

9.  Poldip2 knockdown protects against lipopolysaccharide-induced acute lung injury via Nox4/Nrf2/NF-κB signaling pathway.

Authors:  Yueguo Wang; Wenwen Wang; Shusheng Zhou; Yulan Wang; Obed Cudjoe; Yu Cha; Chunyan Wang; Xiaoguang Cao; Wei Liu; Kui Jin
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

10.  Poldip2 controls leukocyte infiltration into the ischemic brain by regulating focal adhesion kinase-mediated VCAM-1 induction.

Authors:  Lori N Eidson; Qingzeng Gao; Hongyan Qu; Daniel S Kikuchi; Ana Carolina P Campos; Elizabeth A Faidley; Yu-Yo Sun; Chia-Yi Kuan; Rosana L Pagano; Bernard Lassègue; Malú G Tansey; Kathy K Griendling; Marina S Hernandes
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.